drugset / Trial / NCT01936025

A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test

NCT01936025

Phase 2 Completed 34 enrolled Profil Institute for Metabolic Research GmbH
RandomizedCrossoverDouble-blindTreatment

Summary

The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study. Eligible subjects will be randomized to receive DXM 30 mg, DXM 60 mg, DXM 90 mg alone or in combination with sitagliptin 100 mg, sitagliptin 100 mg alone, or placebo (for DXM and sitagliptin) on in total eight treatment days. An OGTT will be started 1 hour after study drug administration and blood glucose will be measured over the next 4 hours. There will be a 3 to 14-day washout period between doses.

Timeline

Start
2013-10
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg
Subject Dextromethorphan Unknown 60 mg
Subject Dextromethorphan Unknown 90 mg
Subject Sitagliptin Small molecule 100 mg